SEC Filing Summary: Athira Pharma, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Athira Pharma, Inc. (not Leonabio, Inc.) on May 15, 2024. The filing serves as a current report to disclose the issuance of a press release regarding the Company's financial results for the quarter ended March 31, 2024. The Company is an emerging growth company incorporated in Delaware and trades on the Nasdaq Global Select Market under the symbol ATHA.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document acts as a notification that these results were released via a press release (Exhibit 99.1), but the financial data itself is not embedded in the text of this 8-K.
Material Changes
No specific material changes in financial condition or operations are detailed in this text. The filing references the Q1 2024 results but does not provide comparative data against prior periods within the body of this report.
Guidance, Outlook, and Risks
- Disclosure Channels: The Company utilizes its website, investor relations portal, and social media platforms (X, LinkedIn, Instagram, Facebook) to disseminate material information.
- Regulation FD: The filing includes a Regulation FD disclosure statement, noting that information shared through the aforementioned channels may be deemed material.
- Outlook: No specific forward-looking guidance or management commentary regarding future performance is included in this text.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) by reviewing Exhibit 99.1 (the press release dated May 15, 2024), as they are not listed in this summary.
- Confirm the Company's name is Athira Pharma, Inc. (ATHA), noting the discrepancy with the "Leonabio, Inc." label in the request metadata.
- Review the Company's social media channels and investor relations website for any additional material updates referenced in Item 7.01.
- Check for any subsequent filings that may incorporate the Q1 2024 results by reference.